View in EDS

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.

Saved in:
Bibliographic Details
Title: Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Authors: Budde LE; City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ebudde@coh.org., Olszewski AJ; Brown University, Providence, RI, USA., Assouline S; Jewish General Hospital, McGill University, Montreal, Quebec, Canada., Lossos IS; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA., Diefenbach C; Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA., Kamdar M; University of Colorado, Aurora, CO, USA., Ghosh N; Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC, USA., Modi D; Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA., Sabry W; Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada., Naik S; Penn State Cancer Institute, Hershey, PA, USA., Mehta A; University of Alabama at Birmingham, Birmingham, AL, USA., Nakhoda SK; Fox Chase Cancer Center, Philadelphia, PA, USA., Smith SD; Fred Hutchinson Cancer Center, Seattle, WA, USA., Dorritie K; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Jia T; Roche (China) Holding Ltd, Shanghai, China., Pham S; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada., Huw LY; Genentech, Inc., South San Francisco, CA, USA., Jing J; Genentech, Inc., South San Francisco, CA, USA., Wu H; Genentech, Inc., South San Francisco, CA, USA., Ead WS; Genentech, Inc., South San Francisco, CA, USA., To I; Genentech, Inc., South San Francisco, CA, USA., Batlevi CL; Genentech, Inc., South San Francisco, CA, USA., Wei MC; Genentech, Inc., South San Francisco, CA, USA., Chavez JC; Moffitt Cancer Center, Tampa, FL, USA. Julio.C.Chavez@moffitt.org.
Source: Nature medicine [Nat Med] 2024 Jan; Vol. 30 (1), pp. 229-239. Date of Electronic Publication: 2023 Dec 10.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38072960
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Budde+LE%22">Budde LE</searchLink>; City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ebudde@coh.org.<br /><searchLink fieldCode="AU" term="%22Olszewski+AJ%22">Olszewski AJ</searchLink>; Brown University, Providence, RI, USA.<br /><searchLink fieldCode="AU" term="%22Assouline+S%22">Assouline S</searchLink>; Jewish General Hospital, McGill University, Montreal, Quebec, Canada.<br /><searchLink fieldCode="AU" term="%22Lossos+IS%22">Lossos IS</searchLink>; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.<br /><searchLink fieldCode="AU" term="%22Diefenbach+C%22">Diefenbach C</searchLink>; Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Kamdar+M%22">Kamdar M</searchLink>; University of Colorado, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Ghosh+N%22">Ghosh N</searchLink>; Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC, USA.<br /><searchLink fieldCode="AU" term="%22Modi+D%22">Modi D</searchLink>; Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.<br /><searchLink fieldCode="AU" term="%22Sabry+W%22">Sabry W</searchLink>; Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada.<br /><searchLink fieldCode="AU" term="%22Naik+S%22">Naik S</searchLink>; Penn State Cancer Institute, Hershey, PA, USA.<br /><searchLink fieldCode="AU" term="%22Mehta+A%22">Mehta A</searchLink>; University of Alabama at Birmingham, Birmingham, AL, USA.<br /><searchLink fieldCode="AU" term="%22Nakhoda+SK%22">Nakhoda SK</searchLink>; Fox Chase Cancer Center, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Smith+SD%22">Smith SD</searchLink>; Fred Hutchinson Cancer Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Dorritie+K%22">Dorritie K</searchLink>; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Jia+T%22">Jia T</searchLink>; Roche (China) Holding Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Pham+S%22">Pham S</searchLink>; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Huw+LY%22">Huw LY</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Jing+J%22">Jing J</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wu+H%22">Wu H</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ead+WS%22">Ead WS</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22To+I%22">To I</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Batlevi+CL%22">Batlevi CL</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wei+MC%22">Wei MC</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chavez+JC%22">Chavez JC</searchLink>; Moffitt Cancer Center, Tampa, FL, USA. Julio.C.Chavez@moffitt.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2024 Jan; Vol. 30 (1), pp. 229-239. <i>Date of Electronic Publication: </i>2023 Dec 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38072960
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-023-02726-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 229
    Titles:
      – TitleFull: Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Budde LE
      – PersonEntity:
          Name:
            NameFull: Olszewski AJ
      – PersonEntity:
          Name:
            NameFull: Assouline S
      – PersonEntity:
          Name:
            NameFull: Lossos IS
      – PersonEntity:
          Name:
            NameFull: Diefenbach C
      – PersonEntity:
          Name:
            NameFull: Kamdar M
      – PersonEntity:
          Name:
            NameFull: Ghosh N
      – PersonEntity:
          Name:
            NameFull: Modi D
      – PersonEntity:
          Name:
            NameFull: Sabry W
      – PersonEntity:
          Name:
            NameFull: Naik S
      – PersonEntity:
          Name:
            NameFull: Mehta A
      – PersonEntity:
          Name:
            NameFull: Nakhoda SK
      – PersonEntity:
          Name:
            NameFull: Smith SD
      – PersonEntity:
          Name:
            NameFull: Dorritie K
      – PersonEntity:
          Name:
            NameFull: Jia T
      – PersonEntity:
          Name:
            NameFull: Pham S
      – PersonEntity:
          Name:
            NameFull: Huw LY
      – PersonEntity:
          Name:
            NameFull: Jing J
      – PersonEntity:
          Name:
            NameFull: Wu H
      – PersonEntity:
          Name:
            NameFull: Ead WS
      – PersonEntity:
          Name:
            NameFull: To I
      – PersonEntity:
          Name:
            NameFull: Batlevi CL
      – PersonEntity:
          Name:
            NameFull: Wei MC
      – PersonEntity:
          Name:
            NameFull: Chavez JC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2024 Jan
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1